Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis

BACKGROUND: Valganciclovir is the most commonly used antiviral for cytomegalovirus (CMV) prophylaxis in solid organ transplant recipients. However, there are limited clinical outcomes-supported data available to guide valganciclovir dosing in patients on hemodialysis (HD). This study aimed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Ecabert, Danielle, Pham, Christine, Pierce, Brett J, Musick, William L, Nguyen, Duc T, Graviss, Edward A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501296/
https://www.ncbi.nlm.nih.gov/pubmed/34646907
http://dx.doi.org/10.1093/ofid/ofab436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501296/
https://www.ncbi.nlm.nih.gov/pubmed/34646907
http://dx.doi.org/10.1093/ofid/ofab436

Ejemplares similares